Search Clinical Trials
Completed
Multisite Controlled Trial of Cocaine Vaccine (External Link)
This 18-week, placebo-controlled randomized clinical trial among 300 cocaine dependent patients is designed to test the efficacy of a newly developed active vaccine against cocaine (TA-CD). TA-CD vaccine consists of …
Baylor Role:
Lead Sponsor
Completed
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer (External Link)
Patients will be screened within 6 weeks prior to Week 1. A total of 3 cohorts, consisting of 3 to 6 patients each, are planned to receive five to eight …
Baylor Role:
Collaborator
Completed
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR (External Link)
To participate in this study, patients will need to have given informed consent to have a bone marrow transplant. Before receiving the tetanus vaccine, we would like to test the …
Baylor Role:
Collaborator
Completed
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells (External Link)
Previously, some of the cancer cells taken from the patients body were separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was put …
Baylor Role:
Lead Sponsor
Completed
Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer (External Link)
OBJECTIVES: Primary - Evaluate the safety and tolerance of NY-ESO-1/LAGE-1 class-I and class-II vaccine administered subcutaneously in patients with androgen-independent metastatic prostate cancer. Secondary - Compare the response induced by …
Baylor Role:
Lead Sponsor
Completed
Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection (External Link)
There is an urgent need for new tools to control human hookworm infection and to reduce its burden of disease in developing countries. This is especially true for children and …
Baylor Role:
Lead Sponsor
Completed
Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change (External Link)
This study is a 43-month prospective, randomized, double-blind, placebo-controlled comparison of immunogenicity and reactogenicity elicited by BioThrax given by different routes of administration (SQ versus IM) and dosing regimens (as …
Baylor Role:
Collaborator
Completed
Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy (External Link)
Tumor cells from subjects with high-risk neuroblastoma will be obtained at the time of presentation and initial diagnosis, during routine surveillance of bone marrow disease status, or at the time …
Completed
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine (External Link)
Before starting in the treatment part of this study, leukemia cells and skin fibroblasts will be collected from the patient - called "procurement" - to allow us to make the …
Baylor Role:
Lead Sponsor
Completed
Control of Epidemic Influenza Through a School-based Influenza Vaccination Program (External Link)
This study was conducted in three phases. The first phase spanned from 1998-2003 (PubMed ID:14706961; PubMed ID: 12915495) and the second phase spanned from 2003-2007 (PubMedID: 18401289; PubMed ID: 17698577). …
Baylor Role:
Lead Sponsor